Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
SURMOUNT-1 Trial (New England Journal of Medicine, 2022) Randomized, double-blind, placebo-controlled 2,539 participants 72 weeks NCT04184622 Tirzepatide 5 mg -16.0% Mean body weight reduction Tirzepatide 10 mg -21.4% Mean body weight reduction Tirzepatide 15 mg -22.5% Mean body weight reduction Placebo group: -2.4% All results statistically significant (p 27 with Comorbidities Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss
and Langan et al
If you are interested in medications to correct your appetite regulation, we will carefully guide you to the correct treatment option
Trumps deal caps that advantage
US$ 23.07
US$ 21.89
US$ 22.60
US$ 28.65
